<DOC>
	<DOC>NCT01210482</DOC>
	<brief_summary>The objective of this investigation is to determine the following items in all patients receiving Torisel for a certain period after marketing: 1. Confirmation of efficacy and safety for medical practice use. 2. Investigation of factors that may influence the incidence of adverse events (Particularly priority investigation items). 3. Investigation of the incidence status and the risk factors for interstitial lung diseases.</brief_summary>
	<brief_title>Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>Implemented as a Drug Use Investigation by Central Registration System</detailed_description>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma). Patients not administered Torisel. Patients with a history of severe hypersensitivity to temsirolimus, sirolimus derivative, or any of their components and/or derivatives.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Torisel</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>